

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

**0 316 594
A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88117304.1

(51) Int. Cl.⁴ **C07D 263/20 , C07D 413/10 ,
A61K 31/42**

(22) Date of filing: 18.10.88

(30) Priority: 21.10.87 US 110837

(43) Date of publication of application:
24.05.89 Bulletin 89/21

(84) Designated Contracting States:
AT BE CH DE ES FR GB GR IT LI LU NL SE

(71) Applicant: **E.I. DU PONT DE NEMOURS AND
COMPANY**
1007 Market Street
Wilmington Delaware 19898(US)

(72) Inventor: **Brittelli, David Ross**
90 Hopewell Road
Nottingham Pennsylvania 19362(US)
Inventor: **Gregory, Walter Adelman**
104 Rockingham Drive
Wilmington Delaware 19803(US)
Inventor: **Corless, Peter Franklin**
48 Main Street
Southborough Massachusetts 01772(US)
Inventor: **Park, Chung-Ho**
5 Woodley Circle
Wilmington Delaware 19803(US)

(74) Representative: **von Kreisler, Alek,**
Dipl.-Chem. et al
Patentanwälte Von Kreisler-Selting-Werner
Deichmannhaus am Hauptbahnhof
D-5000 Köln 1(DE)

(54) **Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents.**

(57) Aminomethyl oxooxazolidinyl ethenylbenzene derivatives, including the nitriles, sulfoxides, acetamides and nitro compounds, such as 1-N-[3-[4-(E-1-methyl-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, possess useful antibacterial activity.

EP 0 316 594 A1

AMINOMETHYL OXOOXAZOLIDINYL ETHENYLBENZENE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS


Technical Field

This invention relates to novel aminomethyl oxooxazolidinyl ethenylbenzene derivatives, their preparation, to pharmaceutical compositions containing them, and to methods of using them to alleviate bacterial infections.

Background of the Invention

At the present time, no existing antibacterial product provides all features deemed advantageous. There is continual development of resistance by bacterial strains. A reduction of allergic reactions and of irritation at the site of injection, and greater biological half-life (i.e., longer in vivo activity) are currently desirable features for antibacterial products.

U.S. Patent 4,128,654 issued to Fugitt et al. on December 5, 1978, discloses, among others, compounds of the formula:



where

A = RS(O)_n;


X = Cl, Br or F;

R = C₁-C₃ alkyl; and

n = 0, 1 or 2.


The compounds are disclosed as being useful in controlling fungal and bacterial diseases of plants.

U.S. Reissue Patent 29,607 reissued April 11, 1978 discloses derivatives of 5-hydroxymethyl-3-substituted-2-oxazolidinones of the formula:




where R is H, F, CH₃, or CF₃. Such compounds are described as having antidepressive, tranquilizing, sedative, and antiinflammatory properties.

U.S. Patent 4,250,318, which was issued on February 10, 1981, discloses antidepressant compounds of the formula:



where R' can be, among others, a para-n-pentylamino group, an SR_1 group where R_1 is C_1 - C_5 alkyl, or an acetylmethylthio group.

U.S. Patent 4,340,606, issued to Fugitt et al. on July 20, 1982, discloses antibacterial agents of the general formula:




where

$R_1 = \text{CH}_3, \text{C}_2\text{H}_5, \text{CF}_2\text{H}, \text{CF}_3$ or $\text{CF}_2\text{CF}_2\text{H}$; and

$X = \text{OR}_2$ ($R_2 = \text{H}$ or various acyl moieties).

U.S. Patent 3,687,965, issued to Fauran et al. on August 29, 1972, discloses compounds of the formula:



where

$-\text{N}(\text{R}_1)(\text{R}_2)$ represents either dialkylamino radical in which the alkyl portions have one to five carbon atoms, or a heterocyclic amino radical which may be substituted by an alkyl radical having one to five carbon atoms or by a pyrrolidinocarbonylmethyl radical, and

R_3 represents a phenyl radical which may be substituted by one or more of the following radicals:

an alkoxy radical having one to five carbon atoms;


a halogen atom;

a trifluoromethyl radical, or

a carboxyl radical which may be esterified.

The patent states that these compounds possess hypotensive, vasodilatory, spasmolytic, sedative, myorelaxant, analgesic and antiinflammatory properties. There is no mention of antibacterial properties.

Belgian Patent 892,270, published August 25, 1982, discloses monoamine oxidase inhibitors of the formula



where


R is H, C_1 - C_4 alkyl or propargyl;

Ar is phenyl, optionally substituted by halo or trifluoromethyl;

n is 0 or 1; and


X is $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$, an acetylene group or $-\text{CH}_2\text{O}-$.

U.S. Patent 4,461,773 issued to W. A. Gregory on July 24, 1984 discloses antibacterial agents of the formula



wherein, for the *l*, and mixtures of the *d* and *l* stereoisomers of the compound,

R_1 is R_2SO_2 ,



R_2 is $-NR_3R_4$, $-N(OR_3)R_4$, $-N_3$, $-NHNH_2$, $-NX_2$, $-NR_6X$, $-NXZ$, $-NH\overset{\overset{O}{\parallel}}{C}R_7$, $-NZ\overset{\overset{O}{\parallel}}{C}R_7$

or $-N=S(O)_nR_8R_9$;

R_3 and R_4 are independently H, alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons;



R_5 is NR_3R_4 or OR_3 ;

R_6 is alkyl of 1-4 carbons;

R_7 is alkyl of 1-4 carbons, optionally substituted with one or more halogens;

R_8 and R_9 are independently alkyl of 1-4 carbons or, taken together are $-(CH_2)_p$;

R_{10} is H, alkyl of 1-3 carbons,



R_{11} is alkyl of 1-12 carbons;

R_{12} is H, alkyl of 1-5 carbons, CH_2OH or CH_2SH ;

X is Cl, Br or I;

Z is a physiologically acceptable cation;

m is 2 or 3;


n is 0 or 1; and

p is 3, 4 or 5;

and when R_{10} is alkyl of 1-3 carbons, R_1 can also be $CH_3S(O)_q$ where q is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

European Patent Application 127,902, published December 12, 1984, and 184,170, published June 11, 1986, disclose antibacterial agents of the formula:



wherein, for the ℓ , and mixtures of the d and ℓ stereoisomers of the compound,

A is $-\text{NO}_2$, $-\text{S}(\text{O})_n\text{R}_1$, $-\text{S}(\text{O})_2-\text{N}=\text{S}(\text{O})_p\text{R}_2\text{R}_3$, $-\text{SH}$,

$-\text{S}(\text{O})_2\text{NR}_7$, $-\text{S}(\text{O})_2\text{NR}_7$, $-\text{COR}_{23}$, $-\text{COR}_{25}$, $-\text{CONR}_5\text{R}_6$, $-\text{C}(\text{R}_6)(\text{NR}_7)\text{R}_{23}$.

$-\text{C}(\text{R}_6)(\text{OR}_8)\text{R}_{23}$, $-\text{C}(\text{R}_6)(\text{OR}_8)\text{R}_{25}$, $-\text{C}(\text{R}_6)(\text{O}=\text{C}\text{R}_8)\text{R}_{23}$, $-\text{C}(\text{R}_6)(\text{O}=\text{C}\text{R}_8)\text{R}_{25}$.

$-\text{CN}$, $-\text{OR}_5$, halogen, $-\text{NR}_5\text{R}_6$, $-\text{NCOR}_4$, $-\text{NS}(\text{O})_n\text{R}_4$, $\text{CR}_{23}(\text{OR}_{16})\text{OR}_{17}$, $-\text{C}(\text{R}_9)(\text{NR}_5\text{R}_6)\text{R}_{23}$, alkyl

of 1 to 8 carbons, optionally substituted with one or more halogen atoms, OH, =O other than at alpha position, $\text{S}(\text{O})_n\text{R}_{24}$, NR_5R_6 , alkenyl of 2-5 carbons, alkynyl of 2-5 carbons or cycloalkyl of 3-8 carbons;

R_1 is C_1 - C_4 alkyl, optionally substituted with one or more halogen atoms, OH, CN, NR_5R_6 or CO_2R_8 ; C_2 - C_4 alkenyl; $-\text{NR}_9\text{R}_{10}$; $-\text{N}_3$;

$-\text{NH}-\text{C}(\text{O})\text{R}_4$; $-\text{NZ}-\text{C}(\text{O})\text{R}_4$; $-\text{NX}_2$; NR_9X ; $-\text{NXZ}^+$;

R_2 and R_3 are independently C_1 - C_2 alkyl or, taken together are $-(\text{CH}_2)_q$;

R_4 is alkyl of 1-4 carbons, optionally substituted with one or more halogens;

R_5 and R_6 are independently H, alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons;

R_7 is $-\text{NR}_5\text{R}_6$, $-\text{OR}_5$ or

$\text{NH}-\text{C}(\text{O})\text{R}_5$;

R_8 is H or alkyl of 1-4 carbons;

R_9 is H, C_1 - C_4 alkyl or C_3 - C_8 cycloalkyl;

R_{10} is H, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_3 - C_4 cycloalkyl, $-\text{OR}_8$ or $-\text{NR}_{11}\text{R}_{11A}$;

R_{11} and R_{11A} are independently H or C_1 - C_4 alkyl, or taken together, are $-(\text{CH}_2)_r$;

X is Cl, Br or I;

Y is H, F, Cl, Br, alkyl of 1-3 carbons, or NO_2 , or A and Y taken together can be $-\text{O}-(\text{CH}_2)_t\text{O}-$;

Z is a physiologically acceptable cation;


n is 0, 1 or 2;

p is 0 or 1;

q is 3, 4 or 5;

r is 4 or 5;

t is 1, 2 or 3;



R_{12} is H, C₁-C₁₀ alkyl or C₃-C₈ cycloalkyl;

R_{13} is H; C₁-C₄ alkyl optionally substituted with one or more halogen atoms;

C₂-C₄ alkenyl; C₃-C₄ cycloalkyl; phenyl; -CH₂OR₁₅; -CH(OR₁₆)OR₁₇; -CH₂S(O)_vR₁₄;

$\begin{array}{c} \text{O} \\ || \\ \text{C} \end{array} \text{R}_{15}$; -OR₁₈; -SR₁₄; -CH₂N₃; the aminoalkyl groups derived from α -amino acids such as glycine, L-alanine, L-cysteine, L-proline, and D-alanine; -NR₁₉R₂₀; or C(NH₂)R₂₁R₂₂;

R₁₄ is C₁-C₄ alkyl, optionally substituted with one or more halogen atoms;

R₁₅ is H or C₁-C₄ alkyl, optionally substituted with one or more halogen atoms;

R₁₆ and R₁₇ are independently C₁-C₄ alkyl or, taken together, are -(CH₂)_m;

R₁₈ is C₁-C₄ alkyl or C₇-C₁₁ aralkyl;

R₁₉ and R₂₀ are independently H or C₁-C₂ alkyl;

R₂₁ and R₂₂ are independently H, C₁-C₄ alkyl, C₃-C₆ cycloalkyl, phenyl or, taken together, are -(CH₂)_s;

u is 1 or 2;

v is 0, 1 or 2;

m is 2 or 3;

s is 2, 3, 4 or 5; and


R₂₃ is H, alkyl of 1-8 carbons optionally substituted with one or more halogens, or cycloalkyl of 3-8 carbons;

R₂₄ is alkyl of 1-4 carbons or cycloalkyl of 3-8 carbons;


R₂₅ is alkyl of 1-4 carbons substituted with one or more of -S(O)_nR₂₄, -OR₈,

$\begin{array}{c} \text{O} \\ || \\ -\text{O} \text{ C } \end{array} \text{R}_8$, -NR₅R₆, or alkenyl of 2-5 carbons optionally substituted with CHO; or a pharmaceutically suitable salt thereof; provided that;


1) when A is CH₃S-, then B is not



2) when A is CH₃SO₂-, then B is not



3) when A is H₂NSO₂- and B is



then R₁₂ is H;

4) when A is -CN, B is not -N₃;

5) when A is (CH₃)₂CH, B is not NHCOCH₂Cl;


6) when A is OR₅, then B is not NH₂;

7) when A is F, then B is not NHCO₂CH₃.

None of the above-mentioned references suggest the novel antibacterial compounds of this invention.


Summary of the Invention

According to the present invention, there is provided an oxazolidinone of the formula:




(I)

wherein for the *l* isomer or racemic mixtures containing it




u is 1 or 2:

- R*₄ is H, alkyl of 1-10 carbon atoms, or cycloalkyl of 3-8 carbon atoms;
*R*₅ is H, alkyl of 1-4 carbon atoms optionally substituted with one or more halogen atoms, alkenyl of 2-4 carbon atoms, cycloalkyl of 3-4 carbon atoms, phenyl; OR₆, or CH₂OR₄;
*R*₆ is alkyl of 1-4 carbon atoms optionally substituted with one or more halogen atoms;
*R*₇ is H, CH₃, C₂H₅, F or OH;
*R*₁ independently is H, CF₃, alkyl of 1-3 carbon atoms optionally substituted with one halogen, phenyl, or phenyl optionally substituted with one or more halogen atoms, or taken together with *R*₂ forms a 5-, 6-, or 7-membered ring of the formula:



or

- (CH₂)_p-, when *R*₃ is an electron-withdrawing group;
*R*₂ and *R*₃ independently are an electron-withdrawing group, H, CF₃, alkyl of 1-3 carbon atoms optionally substituted with one halogen, or phenyl, provided at least one of *R*₂ or *R*₃ is an electron-withdrawing group,
 or
*R*₂ and *R*₃ taken together form a 5, 6 or 7-membered ring of the formula:



- m* is 1, 2 or 3;
n is 2, 3 or 4;
p is 3, 4 or 5; and
X is CH₂, O, S, or NR where *R* is H or alkyl of 1-5 carbon atoms;

or a pharmaceutically suitable salt thereof.

Also provided is a pharmaceutical composition consisting essentially of a suitable pharmaceutical carrier and a compound of Formula (I) and a method of using a compound of Formula (I) to treat bacterial infection in a mammal.

- 5 Further provided is a process for preparing compounds of Formula (I), such a process being described in detail hereinafter.

Preferred Embodiments

10

Preferred compounds are the oxazolidinones of Formula (I) where:


(a) B is

$\text{-NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}_5$; where R_5 is H, CH_3 , OR_6 , CHCl_2 , CH_2Cl , CH_2OH or CH_2OCH_3 ; or

15

(b) R_1 independently is H or alkyl of 1-3 carbon atoms, or is taken together with R_2 to form a 5- or 6-membered ring of the formula:

20



25

where m is 1 or 2; or

(c) R_2 independently is an electron-withdrawing group; or

(d) R_3 independently is H, alkyl of 1-3 carbon atoms or phenyl.

30

More preferred compounds are the oxazolidinones of Formula (I) where:


(a) B is

$\text{-NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{CH}_3$; or

35

(b) R_1 independently is H, CH_3 or C_2H_5 , or is taken together with R_2 to form a 5- or 6-membered ring of the formula:

40



45

where m is 1 or 2; or

(c) R_2 independently is CN or NO_2 ; or

(d) R_3 independently is H, CH_3 or C_2H_5

50

Specifically preferred are the following compounds:


- (1)-N-[3-[4-(E-1-methyl-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide;
- (1)-N-[3-[4-(3-oxo-1-cyclohexen-1-yl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide;
- (1)-N-[3-[4-(E-2-nitroethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide;
- (1)-N-[3-[4-(E-1-methyl-2-nitroethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide

55

Detailed Description

The compounds of Formula (I) contain at least one chiral center, and as such exist as two individual isomers or as a mixture of both. This invention relates to the levorotatory isomer (*l*) which for many of the compounds in this invention can be referred to as the (S) isomer, as well as mixtures containing both the (R) and (S) isomers. Additional chiral centers may be present in any of the R groups and/or B and this invention relates to all possible stereoisomers in these groups.

For the purposes of this invention, the *l*-isomer of compounds of Formula (I) is intended to mean compounds of the configuration depicted; when B is NHAc, and closely related groups, this isomer is described as the (S)-isomer in the Cahn-Ingold-Prelog nomenclature:



(I)

Furthermore, a different type of stereoisomerism exists when the compounds of Formula (I) contain groups R_1 and R_2 which are different. Such isomers which may be interconverted by torsion around double bonds are classically termed geometric isomers or *cis-trans*-isomers. The newer method of describing them is based on the Cahn-Ingold-Prelog system by which two groups at each carbon atom of the double bond are ranked by the sequence rules. Then that isomer with two higher ranking groups on the same side of the double bond is called *Z* (for the German word *zusammen* meaning *together*); the other is *E* (for *entgegen* meaning *opposite*). This invention relates to both *E*- or *Z*-isomers separately or mixed together.


The concept of the electron-withdrawing group derives from consideration of the effect of substituents on the rate of various reactions. The constant σ may be defined, which is characteristic for a particular group. The σ values are numbers which sum up the total electrical effects (field plus resonance) of a group. A positive value of σ indicates an electron-withdrawing group. Different σ values have been developed for different positions on the benzene ring; we choose σ_p as most appropriate for defining the class of substituents operable in this application. (A discussion of the concept of electron-withdrawing groups may be found in: J. March, *Advanced Organic Chemistry, Reactions, Mechanisms, and Structure*, 2nd Edition, McGraw-Hill, New York, 1977, Chapters 2 and 9, as well as other standard texts on advanced organic chemistry).

The substituents conferring particular antibacterial activity to the subject compounds of this application are unsaturated functional groups having σ_p greater than about 0.20. A listing of groups and their σ_p constants may be found in C. Hansch and A. Leo, *Substituent Constants for Correlation Analysis in Chemistry and Biology*, John Wiley and Sons, New York, 1979. Some representative examples of electron-withdrawing groups are the nitro ($-\text{NO}_2$), cyano ($-\text{CN}$), formyl ($-\text{CHO}$), carboxamido ($-\text{C}(=\text{O})\text{NH}_2$), N-methyl carboxamido ($-\text{C}(=\text{O})\text{NHCH}_3$), acetyl ($-\text{C}(=\text{O})\text{CH}_3$), propionyl ($-\text{C}(=\text{O})\text{C}_2\text{H}_5$), carbomethoxy ($-\text{C}(=\text{O})\text{OCH}_3$), methylsulfinyl ($-\text{S}(\text{O})\text{CH}_3$), methylsulfonyl ($-\text{SO}_2\text{CH}_3$), fluoromethylsulfinyl ($-\text{SOCH}_2\text{F}$), trifluoromethylsulfonyl ($-\text{SO}_2\text{CF}_3$), and dimethylphosphinyl ($-\text{PO}(\text{CH}_3)_2$) groups.

50 Synthesis

Compounds of Formula (I) can be prepared as follows:

55 Scheme 1:



10

Wherein R_1 independently is H, CF_3 , alkyl of 1-3 carbon atoms optionally substituted with one halogen, or phenyl. R_2 and R_3 independently are H, CF_3 , alkyl of 1-3 carbon atoms optionally substituted with one halogen, phenyl or CN, provided that only one of R_2 and R_3 is CN and B is as described previously; provided, R_5 in B is not one carbon atom substituted with one or more halogen atoms.

15

Solvents such as 1,2-dimethoxyethane, dioxane, bis-(2-methoxyethyl)ether, N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAc), acetonitrile, ethanol or other alcohols may be used. Suitable bases include sodium hydride, butyllithium or an alkoxide. The reaction is typically carried out by adding a base to a solution of the phosphonate (III) at 0 to 20° C followed by addition of the substrate (II). The reaction mixture is stirred from about room temperature to 60° C for 1 to 2 hours, the solvent is removed under reduced pressure and the residue is triturated with water. The resulting crude product which is usually a mixture of E and Z isomers with E isomer predominant, is separated and purified by conventional means. The starting compound (II) may be d,l- (the racemate) or the l-isomer.


20

The compounds of Formula (II) are prepared by the process previously described in published European applications 127,902 and 184,170. Compounds wherein R_5 is one carbon atom substituted with one or more halogen atoms can be prepared by reaction of compound (I) (B is NH_2) with one or more halogen-substituted acetyl chlorides or acetic anhydrides in the presence of a base. Solvents such as 1,2-dimethoxyethane, dioxane, acetonitrile, tetrahydrofuran, or DMF may be used. Suitable bases include triethylamine or pyridine.

25

Scheme 2:

30



40


Compounds of Formula (I) which may be prepared using the procedures of Scheme 2 are those where R_1 is H, and R_2 and R_3 independently are both electron-withdrawing groups previously defined except that when one of R_2 or R_3 is NO_2 , the remaining R_2 or R_3 group can be an electron-withdrawing group including another NO_2 group or H, CF_3 , alkyl of 1-3 carbon atoms optionally substituted with one or more halogen atoms, or phenyl. The reaction is typically carried out in an aprotic solvent such as benzene or toluene under reflux in the presence of catalytic amounts of a carboxylic acid such as acetic acid and an amine such as piperidine with azeotropic removal of water. The solvent is then removed under reduced pressure

45


and the desired product is isolated as previously described.

Compounds of Formula (VI) are iodinated using iodine and silver trifluoroacetate or iodine monochloride in solvents such as chloroform, acetonitrile, acetic acid or mixtures of solvents thereof at 0° to 60° C. After the reaction mixture is stirred for 1 to 24 hours, the resulting silver halide was filtered off, the solvent was removed under reduced pressure and the residue was triturated with distilled water. The crude product obtained by filtration is purified by recrystallization from suitable solvents such as acetonitrile with the aid of activated charcoal. The iodocompounds (V) are then converted to the aldehydes (II) by addition of carbon monoxide in suitable solvents such as toluene, THF, glyme and DMF or mixtures thereof at 10° to 70° C in the presence of tributyltin hydride and tetrakis(triphenylphosphine)palladium(O).

Scheme 3:



Compounds of Formula (I) where R₁ is H and R₂ and R₃ are taken together to form a 5, 6 or 7-membered ring of formula:



where n is 2, 3,

or 4;

X is CH₂, O,

S, or NR where R

is H or alkyl of

1-5 carbon

atoms, or a


pharmaceutically

suitable salt

thereof.

may be prepared by reaction of the cyclic ylides of Formula (VII) with compounds of Formula (II) in Scheme 3. The cyclic ylides of Formula (VII) can be prepared by procedures describe in H. O. House and H. Barad, J. Org. Chem., 28, 90 (1963).

Compounds of Formula (I) where R₁ is taken together with R₂ to form a 5-membered ring of Formula (VIII)



may be prepared according to synthetic Scheme 4.

Scheme 4:


5

10

15

20

25



Compounds of Formula (IX) which are prepared by the process described in published European Patent Applications 127,902 and 184,170 can be converted into diketone (X) by reaction with the anion of *t*-butyl acetoacetate in an aprotic solvent such as THF or DMF. Suitable bases to generate the anion include sodium hydride, potassium hydride, or potassium *t*-butoxide. The reaction is carried out from 0° to room temperature. Compounds (X) can be decarboxylated upon treatment with refluxing aqueous hydrochloric acid.

Finally a suitable base such as proline, morpholine, pyrrolidine, or potassium *t*-butoxide can be used to convert diketone (XI) into (VIII). Solvents such as benzene, toluene, or *t*-butanol can be used. The reaction temperature may be from room temperature to 130° C.

Compounds of Formula (VIII) can be used to prepare lactones (XII) or lactams (XIII) (Scheme 5).


40

Scheme 5:

45

50

55




25 Compounds of Formula (XIV) may be derived from reaction of gaseous hydrogen chloride with (VIII). Methylene chloride, dioxane, chloroform, or THF may be used as solvents and the reaction temperature can be from 0° to 80° C. Bayer-Villiger oxidation of (XIV) with either trifluoroperacetic acid or *m*-chloroperbenzoic acid (MCPBA) in solvents such as methylene chloride, benzene, or THF at temperatures from 0° to 80° C followed by treatment of the resulting oxidation products with a base such as pyridine, triethylamine, or 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in solvents such as methylene chloride, benzene, toluene, or THF at room temperature to 110° C may convert (XIV) into the desired lactones (XII).

30 Treatment of (VIII) with hydroxyamine hydrochloride in the presence of a base such as pyridine or triethylamine in an alcoholic solvent such as methanol or ethanol at room temperature to 100° C gives the corresponding oxime which undergoes a Beckmann rearrangement upon treatment with phosphorous pentachloride in a solvent such as benzene or toluene at room temperature to 110° C to afford the desired lactams (XIII).


35 By using the same procedures shown in Scheme 5, 7-membered ring lactones and lactams can be obtained from 6-membered enones which are prepared by the procedure described in Example 68 which follows.

40 Compounds of Formula (I) where R_1 is taken together with R_2 to form a 5-membered ring of formula (XV) may be prepared according to




synthetic Scheme 6.

55 Scheme 6:




Compounds of Formula (XVI) are prepared according to the procedure described in Example 58 which follows. Treatment of (XVI) with N-bromosuccinimide (NBS) in refluxing carbon tetrachloride in the presence of a radical initiator such as azobisisobutyronitrile (AIBN) or benzoyl peroxide yields the bromide (XVII). Hydrolysis of (XVII) with aqueous sodium hydroxide or potassium hydroxide in an alcoholic solvent such as methanol or ethanol at room temperature gives lactones (XV, X=O). Liquid ammonia converts (XVII) into lactams (XV, X=NH). The reaction temperature may be from 0° to 100° C. Treatment of (XVII) with potassium thioacetate (KSAc) or thioacetic acid in the presence of triethylamine in a solvent such as acetonitrile, THF, or DMF at 0° C to room temperature followed by hydrolysis of the resulting products with aqueous base such as sodium hydroxide or potassium hydroxide in an alcoholic solvent such as methanol or ethanol at 0° to room temperature gives thiolactones (XV, X=S).

Compounds of Formula (I) where R₁ is taken together with R₂ to form a 6 or 7-membered ring of formula (XVIII) may be prepared according to Scheme 7.




Scheme 7:



25 Treatment of lactones (XVIX) with sodium methoxide in methanol at room temperature to 80 °C gives the hydroxy esters (XX). The hydroxy group in (XX) is converted into mesylate or tosylate with mesyl chloride (MsCl) or tosyl chloride in pyridine at room temperature. The mesylate or tosylate is then displaced with potassium thioacetate (KSAc) or thioacetic acid in the presence of triethylamine in a solvent such as acetonitrile, THF, or DMF at 0 ° to 50 °C to give (XXI). Hydrolysis of (XXI) with aqueous sodium hydroxide or potassium hydroxide in an alcoholic solvent such as methanol or ethanol at 0 °C to room temperature yields the desired compound (XVIII, m = 2 or 3).

30 Compounds of Formula (I) where R₁ is taken together with R₂ to form a 5, 6 or 7-membered ring and R₃ is a cyano group of formula (XXII):




may be prepared by the synthetic transformations shown in Scheme 8.

45 Scheme 8:


50

55



Compounds of Formula (XXIII) where p is 3 and 4 are prepared by the process described in Scheme 4 previously and Example 68 which follows. Alternatively, compounds (XXIII, p=3, 4 or 5) may be prepared according to Scheme 9. Thus, compounds (V) may react with

Scheme 9:



50 iodoenones or bromoenones (XXVI) in the presence of tetrakis(triphenylphosphine)palladium(0) or bis-(triphenylphosphine)palladium(II) chloride in a solvent such as THF, benzene, toluene, or DMF at room temperature to 60 °C to give (XXIII).

Wolff-Kishner reduction of (XXIII) using hydrazine hydrate and potassium hydroxide in diethylene glycol at 150 ° to 200 °C gives (XXIV). Hydroboration of (XXIV) with diborane in THF or ether at 0 °C to room temperature followed by treatment with hydrogen peroxide in the presence of aqueous sodium hydroxide at room temperature to 70 °C and the resulting alcohols oxidized with a suitable oxidizing agent such as pyridinium chlorochromate, pyridinium dichlorochromate, or chromium trioxide in methyl chloride, DMF, or pyridine yields (XXV). Treatment of (XXV) with trimethylsilyl cyanide (TMSCN) in THF, acetonitrile or

methylene chloride at 0° to 50° C followed by dehydration with phosphorus oxychloride at 0° C to room temperature gives (XXII).

Pharmaceutically suitable salts of compounds of Formula (I) can be prepared in a number of ways known in the art. Where B is NH₂, pharmaceutically suitable salts include those resulting from treatment
 5 with acetic, hydrochloric, sulfuric, phosphoric, succinic, fumaric, ascorbic, and glutaric acid.

Example 1

10

Preparation of (1)-N-[3-[4-(E-1-Methyl-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I;
R₁ = CH₃, R₂ = CN, R₃ = R₇ = H, B = NHCOCH₃)

15 A 100 mL 3-necked flask under nitrogen was charged with 0.452 g (11.3 mmol) of sodium hydride (60% dispersion in mineral oil) and 10 mL of dry DMF. The flask was cooled to 5° C and 2.0 g (11.3 mmol) of diethyl cyanomethylphosphonate was added dropwise over 15 minutes. The solution was stirred for 30 minutes after hydrogen evolution was complete and then 2.5 g (9.05 mmol) of a (1)-N-[3-(4-acetylphenyl-2-oxooxazolidin-5-ylmethyl)acetamide was added as a solid. The reaction was allowed to warm to room
 20 temperature and stirred overnight. It was then poured onto 40 g of ice and the mixture was extracted with chloroform and the chloroform solution was dried over magnesium sulfate. The solvent was removed under reduced pressure and the solid residue was recrystallized from acetonitrile to give 1.6 g (59%) of (1)-N-[3-[4-(E-1-methyl-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless crystalline solid, m.p. 176.0-177.0° C. The geometry of the product was shown to be E by nmr analyses. The Z-isomer was
 25 isolated from the mother liquor of recrystallization and purified by liquid chromatography.

Example 2

30

Preparation of (1)-N-[3-[4-(E-2-Cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I;
R₁ = R₃ = R₇ = H, R₂ = CN, B = NHCOCH₃)


35 To a solution of 0.742 g (4.2 mmol; 10% excess) of diethyl cyanophosphonate in 30 mL of THF was added 2.6 mL of n-butyllithium solution (1.6M in hexane) dropwise at below 5° C, and then it was allowed to stir at room temperature for 10 minutes. The mixture was cooled to 0° C and 1 g (3.81 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide was added in one portion. After the mixture was allowed to warm to room temperature and stirred for 1 hour, 5 g of ice was added and the volatile solvents
 40 were removed under reduced pressure. The resulting residue was triturated in water to give 0.9 g of solid which was filtered and recrystallized from 40 mL of ethanol with the help of activated charcoal to give 0.6 g (55%) of (1)-N-[3-[4-(E-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless crystalline solid, m.p. 189-190° C.


By using the procedures described in Examples 1 and 2, additional cyano compounds which were
 45 prepared or can be prepared are illustrated in Table I.

50

55

Table I



EX.	R ₁	R ₂	R ₃	R ₇	B	isomer	m.p. (°C)
1	CH ₃	NC-	H	H	NHCOCH ₃	l	176-177
2	H	NC-	H	H	NHCOCH ₃	l	189-190
3	CH ₃	NC-	H	CH ₃	NHCOCH ₃	l	150-151
4	CH ₃	NC-	H	H	NHCOCH ₃	dl	
5	C ₆ H ₅	NC-	H	H	NHCOCH ₃	dl	
6	p-FC ₆ H ₄	NC-	H	H	NHCOCH ₃	l	217-219
7	C ₂ H ₅	NC-	H	H	NHCOCH ₃	l	
8	n-C ₃ H ₇	NC-	H	H	NHCOCH ₃	l	
9	CH ₃	NC-	CH ₃	H	NHCOCH ₃	l	52-59
10	CH ₃	NC-	CH ₃	H	NHCOCH ₃	dl	
11	CH ₃	CH ₃	NC-	H	NHCOCH ₃	l	146-149
12	H	NC-	CH ₃	H	NHCOCH ₃	l	
13	CH ₃	H	NC-	H	NHCOCH ₃	l	
14	CF ₃	NC-	H	F	NHCO ₂ CH ₃	l	
15	CH ₃	NC-	H	OH	NHCO ₂ CH ₃	l	
16	CH ₃	H	NC-	C ₂ H ₅	NHCO- 	l	
17	H	NC-	H	H	N ₃	l	
18	CH ₃	NC-	H	H	NH ₂	l	

Example 19

5

Preparation of (1)-N-[3-[4-(E-Nitroethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I, $R_1 = R_3 = R_7 = H$, $R_2 = NO_2$, $B = NHCOCH_3$)

10

PART A: Preparation of (1)-N-[3-(4-Iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide

To a mixture containing 23.4 g (0.1 mol) of (1)-N-(3-phenyl-2-oxooxazolidin-5-ylmethyl)acetamide and 29 g (0.13 mol) of silver trifluoroacetate, 300 mL of acetonitrile and 200 mL of chloroform was added 27 g of iodine in one portion and allowed to stir at room temperature overnight. The mixture was filtered and the filtrate was concentrated under reduced pressure to give a brown solid which was triturated with distilled water, filtered and washed thoroughly with distilled water. The resulting solid was recrystallized from 200 mL of acetonitrile (activated charcoal used) to give 27.5 g (77%) of the desired product as a colorless crystalline solid, m.p. 194.5-195.5 °C.

20

Part B: Preparation of (1)-N-[3-(4-Formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide

A mixture containing 31 g (96 mmol) of (1)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]acetamide and 10 g of tetrakis(triphenylphosphine)palladium(0) in 400 mL of dry degassed THF was heated to 50-55 °C under a slight positive pressure of carbon monoxide (using balloon filled with CO). While the temperature and positive pressure of carbon monoxide were being maintained, a solution of 30 mL (25% excess) of tributyltin hydride dissolved in 65 mL of dry toluene, which had previously been flushed with carbon monoxide, was added dropwise over a period of 4 hours. When the addition was complete, 8 mL more of tributyltin hydride dissolved in 65 mL of toluene was added rapidly followed by 35 mL of toluene, and the mixture was stirred at room temperature overnight. The resulting precipitate was filtered, washed three times with toluene to give 19.1 g (85%) of the desired aldehyde, m.p. 171-172 °C.

35

PART C:

A mixture containing 0.5 g (1.9 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 0.25 mL of nitromethane, 2 drops of piperidine and 5 drops of acetic acid in absolute ethanol was heated under reflux for 5 hours. The clear mixture was then allowed to stir at room temperature overnight to give deep yellow precipitate which was collected by filtration. The solid was recrystallized once from ethanol to give 0.19 g (33%) of (1)-N-[3-[4-(E-2-nitroethenyl)phenyl]-2-oxooxazolidin-5-yl-methyl]acetamide as a bright yellow solid, m.p. 216-218 °C.

45

Example 20

Preparation of (1)-N-[3-[4-(E-2-Nitro-2-methylethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide ($R_1 = R_7 = H$, $R_2 = NO_2$, $R_3 = CH_3$, $B = NHCOCH_3$)

A mixture of 3 g (11.4 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 2 mL (27.8 mmol) of nitroethane, 9 drops of piperidine and 30 drops of acetic acid in 125 mL of dry benzene was heated under reflux overnight while water formed from the reaction was removed using a Dean-Stark trap. When the clear reaction mixture was allowed to cool to room temperature, fine yellow precipitate formed. The mixture was diluted with 150 mL of ether, and the solid was collected and recrystallized from a chloroform/n-butyl chloride mixture to give 2.7 g (74%) of the desired product as a bright yellow crystalline

55

solid, m.p. 151.5-152.5 ° C.

Example 21


Preparation of (1)-N-[3-(4-(2-Cyano-2-methylsulfonyl)phenyl)-2-oxooxazolidin-5-ylmethyl]acetamide
(I; $R_1 = R_7 = H$, $R_2 = CN$, $R_3 = CH_3SO$, $B = NHCOCH_3$)

Methylsulfonylacetone nitrile was prepared by adding in small portions 4.6 g (23 mmol) of *m*-chloroperbenzoic acid to a stirred solution of 2 g (23 mmol) of methylthioacetone nitrile in 50 mL of methylene chloride at -20 ° C. When the oxidation was complete as shown by starch-iodide paper test, the solvent was removed under reduced pressure, and the solid residue was triturated with 18 mL of water. The mixture was filtered and water from the aqueous filtrate was removed under reduced pressure to give 2.19 g of the sulfoxide as a colorless solid. When the reaction was carried out at room temperature using an excess of *m*-chloroperbenzoic acid, methylsulfonylacetone nitrile was obtained.

A mixture containing 1 g (3.8 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide, 0.4 g (3.8 mmol) of methylsulfonylacetone nitrile, 3 drops of piperidine and 10 drops of acetic acid in 50 mL of dry benzene was heated under reflux overnight and the water formed during the reaction was removed using a Dean-Stark trap. Solid precipitate obtained on cooling was collected by filtration and recrystallized once from a *n*-butyl chloride/acetonitrile mixture (activated charcoal) to give 0.74 g (83%) of the desired product as a pale yellowish solid, m.p. 158.5-160 ° C.

By using the procedures of Examples 19-25, the following compounds in Table II were prepared or can be prepared.

Table II




Ex.	R ₁	R ₂	R ₃	R ₇	B	iso- mer	m.p. (°C)
19	H	-NO ₂	H	H	NHCOCH ₃	1	216-218
20	H	-NO ₂	CH ₃	H	NHCOCH ₃	1	151.5-152.5
21	H	NC-	CH ₃ SO	H	NHCOCH ₃	1	158.5-160
22	H	-CO ₂ C ₂ H ₅	H	H	NHCOCH ₃	1	135-136
23	CH ₃	-CONH ₂	H	H	NHCOCH ₃	1	203-204
24	H	-SOCH ₃	H	H	NHCOCH ₃	1	62-69
25	J	-CHO	H	H	NHCOCH ₃	1	203-204
26	H	NC-	NC-	H	NHCOCH ₃	1	188.5-190.0
27	H	NC-	-SO ₂ CH ₃	H	NHCOCH ₃	1	222-223
28	H	Ac	Ac	H	NHCOCH ₃	1	151-152
29	H	-NO ₂	C ₂ H ₅	H	NHCOCH ₃	1	155-156
30	H	-NO ₂	n-C ₃ H ₇	H	NHCOCH ₃	1	132.5-133.5
31	H	-SO ₂ CH ₃	-CO ₂ C ₂ H ₅	H	NHCOCH ₃	1	151.5-152.5
32	H	-SOCH ₃	-CO ₂ C ₂ H ₅	H	NHCOCH ₃	1	95-99
33	H	-NO ₂	CF ₃	CH ₃	NHCO- 	1	
34	H	NC-	-SO ₂ CH ₃	F	NHCO ₂ CH ₃	1	

Table II

Ex.	R ₁	R ₂	R ₃	R ₇	B	iso- mer	m.p. (°C)
35	H	Ac	Ac	OH	NHCOCH ₃	1	
36	H	-NO ₂	C ₂ H ₅	C ₂ H ₅	N ₃	1	
37	H	NC-	NC-	H	NCH ₃ COCH ₃	1	

Example 22

Preparation of (1)-N-[3-[4-(E-2-Carboethoxyethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I; R₁ = R₃ = R₇ = H, R₂ = -CO₂C₂H₅, B = NHCOCH₃)

To a slurry of 0.175 g (4.38 mmol) of sodium hydride (60% dispersion in mineral oil) in 10 mL of DMF was added 0.984 g (4.38 mmol) of triethyl phosphonoacetate dropwise at 0 to 5 °C over a period of 15 minutes. The mixture was stirred for 30 minutes after the evolution of hydrogen subsided, and 1 g (3.8 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide was added in one portion. The reaction was allowed to warm to room temperature and stirred overnight. About 5 mL of ice water was added, the mixture was concentrated under reduced pressure and the residue was recrystallized from an isopropanol-methylene chloride mixture to give 0.25 g (22%) of (1)-N-[3-[4-(E-2-carboethoxyethenyl)-phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless solid, m.p. 135.0-136.0 °C.

Example 23

Preparation of (1)-N-[3-[4-(E-1-Methyl-2-carbamidoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I; R₁ = CH₃, R₂ = -CONH₂, R₃ = R₇ = H, B = NHCOCH₃)

The copper (O) catalyst was prepared by the procedure described in Ravindranathan et. al., J. Org. Chem., 47, 4812 (1982). A mixture containing 6.0 g of the copper (O) catalyst, 4.8 g (16 mmol) of (1)-N-[3-[4-(E-1-methyl-2-cyanoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I; R₁ = CH₃, R₂ = CN, R₃ = R₇ = H, B = NHCOCH₃), 100 mL of water and 100 mL of glyme was heated under reflux under nitrogen atmosphere for 8 hours. The catalyst was removed by filtration while still hot, and the filtrate was concentrated under reduced pressure to give a white solid which was purified by flash column chromatography on silica gel to give 3.98 g (78%) of (1)-N-[3-[4-(E-1-methyl-2-carbamidoethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]-acetamide, m.p. 203.0-204.0 °C.

Example 24

Preparation of (1)-N-[3-[4-(2-Methylsulphenylethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I; R₁ = R₃ = R₇ = H, R₂ = -SOCH₃, B = NHCOCH₃)

To a solution of 1.22 g (5.72 mmol) of methylsulphenylmethyldiethylphosphonate [prepared by the procedure in M. Nikolajczyk and A. Zatorski, *Synthesis*, 669 (1973)] in 10 mL of THF cooled at -78°C was added 3.57 mL (5.72 mmol) of *n*-butyllithium (1.6 M in hexane). After stirring for 2 hours, 1.5 g (5.72 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide dissolved in THF was added dropwise and stirred for 3 hours after the addition was complete. The mixture was then allowed to warm to room temperature and stirred for several more hours. The solvent was removed under reduced pressure and the resulting residue was dissolved in water and extracted thoroughly with methylene chloride. After drying, the solvent was removed and the crude residue was purified by flash column chromatography on silica gel to give 275 mg (15%) of (1)-N-[3-[4-(2-methylsulphenylethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as a colorless solid, m.p. $62-69^{\circ}\text{C}$.

Example 25

15

Preparation of (1)-N-[3-[4-(E-2-Formylethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide (I; $\text{R}_1 = \text{R}_3 = \text{R}_7 = \text{H}$, $\text{R}_2 = \text{CHO}$, $\text{B} = \text{NHCOCH}_3$)

To 5 g (11.6 mmol) of (1,3-dioxolan-2-ylmethyl)triphenylphosphonium bromide in 200 mL of glyme was added 7.5 mL of 1.55 M *n*-BuLi at 0°C , then the mixture was stirred at room temperature for 1 hour. To the mixture was added 3 g (11.4 mmol) of (1)-N-[3-(4-formylphenyl)-2-oxooxazolidin-5-ylmethyl]acetamide in one portion at 0°C , slowly heated to reflux for 1 hour and stirred at room temperature overnight. The resulting dark brown, almost clear solution with small amount of brown gum at the bottom was stripped, triturated with ether followed by water and dissolved in 100 mL of acetone. Ten drops of 6 M HCl was added to the solution and stirred at room temperature for 1 hour. The mixture was evaporated to dryness under reduced pressure, triturated with water to give a tan/brown solid which was treated with 10 mL of acetonitrile (not very soluble) and diluted with 100 mL of ether to give 0.99 g of a tan solid. It was recrystallized once from 20 mL of acetonitrile (with activated charcoal) to give 0.71 g (22%) of (1)-N-[3-[4-(E-2-formylethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as light tan needles, m.p. $203-204^{\circ}\text{C}$.

By using the procedure of Example 25, the following compounds shown in Table III can be prepared.


35


40

45

50

55

Table III

Ex.	R ₇	B	n.	X	isomer	m.p. (°C)
38	H	NHCOCH ₃	2.	CH ₂	<u>E</u> . 1	207-208
39	CH ₃	NHCOCH ₃	3.	CH ₂	<u>E</u> . 1	
40	H	NHCOCH ₃	3.	CH ₂	<u>E</u> . 1	118-121
41	H	NHCOCH ₃	2.	O	<u>E</u> . 1	119-122
42	OH	NHCOCH ₃	3.	O	<u>E</u> . 1	
43	H	NHCOCH ₃	4.	O	<u>E</u> . 1	
44	H	NHCOCH ₃	2.	S	<u>E</u> . 1	
45	CH ₃	NH ₂	3.	S	<u>E</u> . 1	
46	F	NHCOCH ₃	4.	S	<u>E</u> . 1	
47	H	NHCOCH ₃	2.	NH	<u>E</u> . 1	
48	CH ₃	NHCOCH ₃	3.	NH	<u>E</u> . 1	
49	OH	NHCOCH ₃	4.	NH	<u>E</u> . 1	
50	H	NHCO 	2.	CH ₂	<u>E</u> . 1	
51	CH ₃	NHCO ₂ CH ₃	3.	O	<u>E</u> . 1	
52	C ₂ H ₅	NHSOCH ₃	2.	CH ₂	<u>E</u> . 1	
53	F	NHSOCH ₃	3.	O	<u>E</u> . 1	
54	OH	N ₃	2.	S	<u>E</u> . 1	
55	H	N ₃	3.	NCH ₃	<u>E</u> . 1	
56	H	N ₃	4.	CH ₂	<u>E</u> . 1	
57	H	N ₃	4.	O	<u>E</u> . 1	

Example 58


Preparation of (1)-N-[3-[4-E-1-Methyl-2-carbomethoxyethenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide
 (1, R₁ = CH₃, R₂ = CO₂CH₃, R₃ = R₇ = H, B = NHCOCH₃)

To a mixture containing 3g (11.4 mmol) of (1)-N-[3-(4-iodophenyl)-2-oxooxazolidin-5-ylmethyl]-acetamide, 10 mL of triethylamine and 30 mL of THF under reflux was added 4 mL of methyl crotonate and

0.86 g of diacetobis(triphenyl-phosphine)palladium(II). After stirring overnight, the mixture was cooled to room temperature, diluted with ether, filtered through a bed of celite. The filtrate was concentrated under reduced pressure, the residue was taken up into methylene chloride and diluted with hexane to precipitate the crude product. The crude product was recrystallized from a methylene chloride-hexane mixture to give 1.0 g (26%) of (1)-N-[3-[4-E-1-methyl-2-carbomethoxyethenyl]phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide as a white solid, m.p. 173-178° C.

By using the procedure described in Example 58, the following compounds in Table IV were prepared or can be prepared.

Table IV



Ex.	R ₁	R ₂	R ₃	R ₇	B	isomer	m.p. (°C)
58	CH ₃	CO ₂ CH ₃	H	N	NHCOCH ₃	1	173-178
59	H	CO ₂ CH ₃	H	H	NHCOCH ₃	1	183-185
60	H	COCH ₃	H	H	NHCOCH ₃	1	175-178
61	H	CON(CH ₃) ₂	H	H	NHCOCH ₃	1	228 dec
62	H	CONH ₂	H	H	NHCOCH ₃	1	249-250 dec
63	CH ₃	CO ₂ CH ₃	H	CH ₃	NH ₂	1	
64	CH ₃	CONH ₂	H	C ₂ H ₅	NHCO ₂ CH ₃	1	
65	CH ₃	COCH ₃	H	F	NHSOCH ₃	1	
66	CH ₃	CO ₂ CH ₃	H	OH	NCH ₃ COCH ₃	1	
67	CH ₃	CO ₂ CH ₃	H	H	N ₃	1	

Example 68

Preparation of (1)-N-[3-[4-(3-oxo-1-cyclohexen-1-yl)phenyl]]-2-oxooxazolidin-5-ylmethyl]acetamide (I, R₁-R₂ = (CH₂)₃CO, R₃ = R₇ = H, B = NHCOCH₃)

Part A: Preparation of (1)-N-[3-[4-(3-Dimethylamino-1-oxopropyl)phenyl]-2-oxooxazolidin-5-yl-methyl]-acetamide


To 20 mL of trifluoroacetic acid at 0-5 °C under nitrogen in an ice-bath was added 2.70 mL of N,N,N',N'-tetramethyldiaminomethane and then 5.0 g of (1)-N-[3-[4-(1-oxoethyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide. The mixture was allowed to warm to room temperature, then heated at 50 °C for 24 hours. The mixture was cooled to room temperature and diluted with water and adjusted to pH 7 by addition of 5% NaHCO₃ solution. The product was extracted into ethyl acetate which was dried (MgSO₄) and evaporated in vacuo to give 3.30 g (55%) of the product.

PART B

To 0.48 g of 50% sodium hydride in mineral oil (washed free of the oil by decantation with petroleum ether) under nitrogen was added 10 mL of glyme and then by pipette 1.10 mL of methyl acetoacetate. The mixture was stirred until hydrogen evolution ceased and all the sodium hydride had reacted, and then treated with a solution of 3.33 g of the product from Part A in 15 mL of glyme and the mixture was heated under reflux; after about 15 minutes, a bright yellow precipitate formed. The mixture was diluted with an equal volume of dry acetonitrile and heated under reflux overnight. The mixture was acidified with acetic acid and then the glyme was removed in vacuo. The residue was dissolved in ethyl acetate, filtered to remove insoluble material, which was washed with water, dried and purified by recrystallization from ethanol to give 0.15 g (5%) of (1)-N-[3-[4-(3-oxo-1-cyclohexen-1-yl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide, m.p. 205.5-207 °C, d.


By using the procedure described in Example 68 and synthesis Schemes 4-7, the following compounds can be prepared.

Table V



Ex.	R ₇	B	X, m	isomer	m.p.(°C)
68	H	NHCOCH ₃	CH ₂ , 2	1	205.5-207
69	H	NHCOCH ₃	CH ₂ , 1	1	
70	OH	NHCOCH ₃	CH ₂ , 1	1	
71	F	NHCOCH ₃	CH ₂ , 1	1	
72	H	NHCOCH ₃	O, 1	1	
73	H	NHCOCH ₃	O, 2	1	
74	H	NHCOCH ₃	O, 3	1	
75	CH ₃	NHSOCH ₃	S, 1	1	
76	C ₂ H ₅	NHCO ₂ CH ₃	S, 2	1	
77	OH	N ₃	S, 3	1	
78	H	NHCO-	NH, 1	1	
79	H	NCH ₃ COCH ₃	NH, 2	1	
80	H	NHCOCH ₃	NH, 3	1	
81	F	NH ₂	NH, 1	1	
82	OH	NHCOCH ₃	NH, 2	1	

By using the procedure described in synthesis discussion Scheme 8, the following compounds can be prepared.

Table VI

Ex.	R ₇	B	p	isomer	m.p. (°C)
83	H	NHCOCH ₃	3	1	
84	H	NHCOCH ₃	4	1	
85	H	NHCOCH ₃	5	1	
86	CH ₃	NHCO ₂ CH ₃	3	1	
87	OH	NHSOCH ₃	4	1	
88	F	N ₃	5	1	
89	C ₂ H ₅	NH ₂	3	1	
90	H	NCH ₃ COCH ₃	4	1	

Dosage Forms

The antibacterial agents of this invention can be administered by any means that produces contact of the active agent with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular agent, and its mode and route of administration; age, health, and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and the effect desired. Usually a daily dosage of active ingredient can be about 5 to 20 milligrams per kilogram of body weight. Ordinarily, when the more potent compounds of this invention are used, 5 to 15, and preferably 5 to 7.5 milligrams per kilogram per day, given in divided doses 2 to 4 times a day or in sustained release form, is effective to obtain desired results. These drugs may also be administered parenterally.

Projected therapeutic levels in humans should be attained by the oral administration of 5-20 mg/kg of body weight given in divided doses two to four times daily. The dosages may be increased in severe or life-threatening infections.

Dosage forms (compositions) suitable for internal administration contain from about 1.0 milligram to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions, it can also be administered parenterally, in sterile liquid dosage forms.

Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, sucrose, manitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to

make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.

5 Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, 10 suitable stabilizing agents, and if necessary, buffer substances. Antioxidants such as sodium bisulfate, sodium sulfite, or ascorbic acid either alone or combined are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a 15 standard reference text in this field.

Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows:

20 Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 75 milligrams of powdered active ingredient, 150 milligrams of lactose, 24 milligrams of talc, and 6 25 milligrams of magnesium stearate.

Soft Gelatin Capsules

30 A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 75 milligrams of the active ingredient. The capsules are washed and dried.

35 Tablets

A large number of tablets are prepared by conventional procedures so that the dosage unit is 75 40 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 250 milligrams for microcrystalline cellulose, 11 milligrams of cornstarch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

45 Injectables

A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution is made isotonic with 50 sodium chloride and sterilized.

Suspensions

55 An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 75 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

Utility

Test results indicate that the novel compounds of this invention are biologically active against gram positive bacteria including multiply antibiotic resistant strains of staphylococci and streptococci. These agents are potentially useful for the treatment of both human and animal bacterial infections including diseases of the respiratory, gastrointestinal genito-urinary systems; blood; interstitial fluids; and soft tissues.

As shown in Table VII compounds of formula I exert an in vitro antibacterial effect. A standard microdilution method (National Committee for Clinical Standards, Tentative standard M7-T. Standard methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, PA. 1982) with Mueller-Hinton broth is used to determine the 24-hour minimal inhibitory concentrations (MIC's) for test strains of Staphylococcus aureus and Escherichia coli.

The in vivo potency of these compounds is exemplified by the data summarized in Table VIII. Determinations of in vivo efficacy are performed by inoculating mice intraperitoneally with cultures of the infecting organism diluted to produce 100% mortality in control animals within twenty-four hours. The culture of S. aureus used to infect the animals was diluted to the required bacterial density using 5% aqueous hog gastric mucin. The compounds are dissolved or suspended in 0.25 % aqueous Methocel® (Methocel®: Hydroxypropyl Methylcellulose, E15 Premium, Dow Chemical Company) for oral administration or sterile distilled water containing 5% dimethylsulfoxide (Fisher Scientific Company, Fairlawn, NJ) for subcutaneous administration. The mice are dosed at one hour and at four hours post-infection. Mortality is recorded daily until test termination seven days post infection. The number of survivors in each treatment group on the seventh day after infection is used in the calculation of the ED₅₀, the dose of compound that protects 50% of the mice (Litchfield, J.T. and Wildoxon. A simplified method for evaluating dose-effect experiments. J. Pharmacol Exp. Ther., 96:99-113, 1949).

Table VII

In Vitro Broth Microdilution Minimal Inhibitory
Concentrations (MIC's)

Ex. No.	Minimum Inhibitory Concentration ($\mu\text{g/mL}$)	
	<u>Staphylococcus aureus</u>	<u>Escherichia coli</u>
1	1	>128
2	4	>128
3	2	>128
5	32	>128
6	>128	>128
7	1	>128
8	2	>128
9	2	>128
11	8	>128
12	1	>128
13	8	>128
19	8	>128
20	0.1	>128
21	4	>128
22	8	>128
23	4	>128
24	8	>128
25	0.5	>128
26	16	>128
27	16	>128
28	16	>128
29	1	>128
30	4	>128
31	16	>128
32	16	>128

Table VII continued)

5 Ex. No.	Minimum Inhibitory Concentration ($\mu\text{g/mL}$)	
	<u>Staphylococcus aureus</u>	<u>Escherichia coli</u>
10 58	2	>128
59	8	>128
60	4	>128
15 61	32	>128
62	32	>128
68	0.5	>128

20

25

30

35

40

45

50

55

Table VIII

In Vivo Activity of Compounds Against
Staphylococcus Aureus in an Acute Lethal Mouse Model

5

Ex. No.

ED₅₀ (mg/kg)

10

Oral AdministrationSubcutaneous Administration

15

20

25

30

35

40

45

50

55

1	1.3	0.8
2	3.5	2.8
3	6.4	5.1
5	>90	>90
6	NT	NT
7	3.1	2.1
8	>90	>90
9	3.8	2.5
11	NT	NT
12	2.9	1.9
13	NT	NT
19	>90	>90
20	14.1	9.1
21	>90	11.8
22	>90	>90
23	26.4	36.2
24	33.3	14.6
25	>80	>80
26	>90	>90
27	>90	>90
28	>90	>90
29	>90	>90
30	>90	>90
31	>90	>90
32	>90	>90
58	NT	46.2
59	NT	>90


Table VIII (continued)

Ex. No.	ED ₅₀ (mg/kg)	
	<u>Oral Administration</u>	<u>Subcutaneous Administration</u>
60	NT	51.9
61	NT	39.5
62	NT	20.4
68	2.4	1.7

NT = Not Tested


Claims

1. A compound having the formula:



(I)

wherein for the *l* isomer or racemic mixtures containing it



u is 1 or 2;


R₄ is H, alkyl of 1-10 carbon atoms, or cycloalkyl of 3-8 carbon atoms;

R₅ is H, alkyl of 1-4 carbon atoms optionally substituted with one or more halogen atoms, alkenyl of 2-4 carbon atoms, cycloalkyl of 3-4 carbon atoms, phenyl; OR₅, or CH₂OR₄;

R₆ is alkyl of 1-4 carbon atoms optionally substituted with one or more halogen atoms;

R₇ is H, CH₃, C₂H₅, F or OH;

R₁ independently is H, CF₃ alkyl of 1-3 carbon atoms optionally substituted with one halogen, phenyl, or phenyl optionally substituted with one or more halogen atoms, or taken together with R₂ forms a 5-, 6-, or 7-membered ring of the formula:




or

-(CH₂)_p- when R₃ is an electron-withdrawing group;

R₂ and R₃ independently are an electron-withdrawing group, H, CF₃, alkyl of 1-3 carbon atoms optionally substituted with one halogen, or phenyl, provided at least one of R₂ or R₃ is an electron-withdrawing group, or

R₂ and R₃ taken together form a 5, 6 or 7-membered ring of the formula:



m is 1, 2 or 3;

n is 2, 3 or 4;


p is 3, 4 or 5; and

X is CH₂, O, S, or NR where R is H or alkyl of 1-5 carbon atoms; or a pharmaceutically suitable salt thereof.

2. A compound of Claim 1 wherein B is

- NHCR₅ where R₅ is H, CH₃, OR₆, CHCl₂, CH₂Cl, CH₂OH or CH₂OCH₃ where R₆ is defined in Claim 1.

3. A compound of Claim 1 wherein R₁ independently is H or alkyl of 1-3 carbon atoms, or is taken together with R₂ to form a 5- or 6-membered ring of the formula:



where m is 1 or 2.


4. A compound of Claim 1 wherein R₂ independently is an electron-withdrawing group.

5. A compound of Claim 1 wherein R₃ independently is H, alkyl of 1-3 carbon atoms, or phenyl.

6. A compound of Claim 1 wherein:

(a) B is -NHCR₅ where R₅ is H, CH₃, OR₆, CHCl₂, CH₂Cl, CH₂OH or CH₂OCH₃ where R₆ is defined in Claim 1.

(b) R₁ independently is H or alkyl of 1-3 carbon atoms, or is taken together with R₂ to form a 5- or 6-membered ring of the formula:




5

10 where m is 1 or 2.

(c) R₂ independently is an electron-withdrawing group.

(d) R₃ independently is H, alkyl of 1-3 carbon atoms, or phenyl.

15 7. A compound of Claim 1 wherein B is



15


8. A compound of Claim 1 wherein R₂ independently is CN or NO₂.

9. A compound of Claim 1 wherein R₃ independently is H, CH₃ or C₂H₅.

10. A compound of Claim 1 wherein:

20


(a) B is



20

(b) R₁ independently is H, CH₃ or C₂H₅, or is taken together with R₂ to form a 5- or 6-membered ring of the formula:

25



30

35

where m is 1 or 2;

(c) R₂ independently is CN or NO₂; and

(d) R₃ independently is H, CH₃ or C₂H₅.

40 11. Compounds of Claims 1 to 10 selected from:

(1)-N-[3-[4-(E-1-methyl-2-cyanoethenyl)-phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide;

(1)-N-[3-[4-(3-oxo-1-cyclohexen-1-yl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide;

(1)-N-[3-[4-(E-2-nitroethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide; and

(1)-N-[3-[4-(E-1-methyl-2-nitroethenyl)phenyl]-2-oxooxazolidin-5-ylmethyl]acetamide.

45


12. A pharmaceutical composition containing essentially of a pharmaceutically suitable carrier and an antibacterial effective amount of a compound of any one of claims 1 to 11.

13. A process for preparing a compound of Claim 1 comprising:

(a) reacting a compound of the formula:

50

55




(II)


wherein B is as described in Claim 1 provided R_5 is not one carbon atom substituted with one or more halogen atoms; and

R_7 is H, CH_3 , C_2H_5 , F or OH;


with (1) when R_1 in (II) independently is H, CF_3 , alkyl of 1-3 carbon atoms optionally substituted with one halogen, or phenyl, phosphonate of the formula:



wherein R_2 and R_3 independently are H, CF_3 , alkyl of 1-3 carbon atoms optionally substituted with one halogen, phenyl, or CN, provided that only one of R_2 and R_3 is CN; or
(2) when R_1 in (II) is H, a compound of the formula:



where R_2 and R_3 independently are both electron-withdrawing groups except that when one of R_2 or R_3 is NO_2 , the other group can be an electron-withdrawing group, including another NO_2 group, or H, CF_3 , alkyl optionally substituted with one or more halogen atoms, or phenyl; or
(3) when R_1 in (II) is H, a cyclic ylide of the formula:



where x and n are as defined in Claim 1.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 88 11 7304

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
D,X	EP-A-0 127 902 (DU PONT DE NEMOURS) * Claims * ----	1-13	C 07 D 263/20 C 07 D 413/10 A 61 K 31/42
D,X	EP-A-0 184 170 (DU PONT DE NEMOURS) * Claims * ----	1-13	
D,A	US-A-3 687 965 (C.P. FAURAN) * Whole document * ----	1,12	
D,A	FR-A-2 500 450 (DELALANDE) * Claims * -----	1,12	
			TECHNICAL FIELDS SEARCHED (Int. Cl. 4)
			C 07 D 263/00 C 07 D 413/00
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 08-12-1988	Examiner HENRY J.C.
<div>CATEGORY OF CITED DOCUMENTS</div> <div><div>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</div><div>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document</div></div>			